PER 6.67% 7.0¢ percheron therapeutics limited

isis loses patent challenge

  1. 131 Posts.
    I wonder what does this latest news means for ANP (if anything?)

    United States Patent and Trademark Office (USPTO) rules in favor of Santaris Pharma A/S in patent re-examination cases for two key Santaris Pharma A/S "Imanishi" patents
    - Patents cover the 2'-4' bicyclic nucleotides known as LNA (Locked Nucleic Acid) or BNA (Bicyclic Nucleic Acid) chemistry that Santaris Pharma A/S has successfully developed to generate effective RNA-targeted therapies for a wide range of diseases
    - Santaris Pharma A/S LNA Drug Platform is rapidly becoming the technology-of-choice for partners interested in developing RNA-targeted medicines for unmet medical needs
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.0¢
Change
-0.005(6.67%)
Mkt cap ! $63.10M
Open High Low Value Volume
7.5¢ 7.5¢ 7.0¢ $25.80K 353.7K

Buyers (Bids)

No. Vol. Price($)
4 34290 7.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 63371 2
View Market Depth
Last trade - 16.10pm 30/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.